Passage Bio (NasdaqGS:PASG) FY Conference Transcript

Summary of Passage Bio FY Conference Call Company Overview - Company: Passage Bio (NasdaqGS:PASG) - Focus: Development of gene therapies for neurodegenerative diseases, specifically frontotemporal dementia (FTD) and Huntington's disease Key Points Clinical Programs - Lead Program: PBFT02 for treating frontotemporal dementia (FTD) with the granulin mutation - Preclinical Program: Huntington's disease targeting CAG repeat expansion - Cash Runway: Expected to last until Q1 2027 with a cash balance of $46 million and a burn rate of $30 million to $35 million per year [2][25] Frontotemporal Dementia (FTD) - Target Population: Patients with granulin mutation; estimated 18,000 patients in the U.S. and Europe [3] - Mechanism: AAV1 gene therapy delivered via nonsurgical injection to cerebrospinal fluid (CSF) to increase progranulin levels, addressing lysosomal dysfunction and neurodegeneration [3][4] - Clinical Trial Status: Ongoing Phase I/II study with nine patients treated to date; two dose levels being evaluated [5][6] - Safety and Efficacy: Preliminary data shows robust increases in CSF progranulin levels, with Dose 1 achieving levels in the mid-20s, significantly above normal [12][14] - Biomarkers: Plasma neurofilaments show a 4% increase in treated patients compared to a 28%-29% annual increase in untreated patients, indicating slowed neurodegeneration [15][16] Safety Profile - Adverse Events: Generally well-tolerated; some serious adverse events (SAEs) reported, including venous sinus thrombus and liver function test (LFT) increases, managed with adjusted immunosuppression [16][17] - Prophylactic Measures: Future cohorts will receive anticoagulation therapy to mitigate thrombotic risks [17] Competitive Landscape - Comparison with Competitors: Other programs, such as Elektor's, faced challenges due to mechanisms that may not effectively deliver progranulin to lysosomes; Passage Bio's approach focuses on direct delivery to CSF [28][30] - Differentiation: Passage Bio's one-time therapy shows durability and higher target engagement compared to competitors, with a focus on treating patients earlier in the disease progression [18][19] Huntington's Disease Program - Target: MSH3 DNA repair protein to reduce CAG repeat expansion, with plans for an optimized intraparenchymal delivery approach [21][22] - Clinical Candidate Timeline: Expected to declare a clinical candidate in the second half of the year, with ongoing preclinical studies [23][46] Future Outlook - Upcoming Data Releases: Anticipated updates on safety and biomarker data for both Dose 1 and Dose 2 in the first half of the year [24][39] - Regulatory Engagement: Seeking feedback on registrational trial design for FTD-GRN to clarify approval requirements [25] Additional Insights - Patient Selection: Moving forward, the company will focus on patients with lower Clinical Dementia Rating (CDR) scores (0.5 and 1) to maximize treatment efficacy [11][31] - Long-term Goals: Aiming to establish a strong clinical profile for both FTD and Huntington's programs, with a focus on early intervention and effective delivery methods [44][45]